Status: Finalised
First registered on:
11/04/2018
Last updated on:
30/03/2020
1. Study identification
EU PAS Register NumberEUPAS23531
Official titleRRA-21430: Acute Pancreatitis in Patients with Type 2 Diabetes Who are New Users of Canagliflozin as Compared with New Users of Other Antihyperglycemic Agents: A Retrospective Cohort Study Using Large Claims Databases in the United States
Study title acronym
Study typeOther: observational, retrospective, new user cohort study
Brief description of the study
Was this study requested by a regulator?Yes: EMA
Is the study required by a Risk Management Plan (RMP)?
EU RMP category 3 (required)
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Centre nameJanssen Research & Development, LLC
Centre locationTitusville, NJ, USA
Details of (Primary) lead investigator
Title Dr
Last name Yuan
First name Zhong
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Not applicable (single centre)
Countries in which this study is being conducted
National study
United States
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed20/03/201820/03/2018
Start date of data collection21/03/201821/03/2018
Start date of data analysis
Date of interim report, if expected
Date of final study report11/09/201804/09/2018
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesJanssen Research & Development, LLC100
Charities
Government body
Research councils
EU funding scheme
5. Contact details for enquiries
Scientific Enquiries
Title Dr
Last name Yuan
First name Zhong
Address line 11125 Trenton-Harbourton Road
Address line 2
Address line 3
CityTitusville, NJ
Postcode
CountryUnited States
Phone number (incl. country code)16097303725
Alternative phone number
Fax number (incl. country code)
Public Enquiries
Title Dr
Last name Yuan
First name Zhong
Address line 11125 Trenton-Harbourton Road
Address line 2
Address line 3
CityTitusville, NJ
Postcode
CountryUnited States
Phone number (incl. country code)16097303725
Alternative phone number
Fax number (incl. country code)
6. Study drug(s) information
Substance class (ATC Code)A10BK02 (canagliflozin)
Single-Constituent (Substance INN)CANAGLIFLOZIN
Product NameInvokana
CountryUnited States
Substance INN(s)CANAGLIFLOZIN
7. Medical conditions to be studied
Medical condition(s)Yes
Pancreatitis acute
8. Population under study
Age
Adults (18 - 44 years)
Adults (45 - 64 years)
Adults (65 - 74 years)
Adults (75 years and over)
Sex
Male
Female
9. Number of subjects
Estimated total number of subjects354000
10. Source of data
Is this study being carried out with an established data source?Yes
Data sources not registered with ENCePP
Truven MarketScan Commercial Claims and Encounters (CCAE) Database, United States
Truven MarketScan Medicare Supplemental (MDCR) Database, United States
Optum Extended Socio-Economic (SES), United States
Sources of data
Administrative database, e.g. claims database
11. Scope of the study
What is the scope of the study?
Disease epidemiology
Risk assessment
comparative safety study
Primary scope : comparative safety study
12. Main objective(s)
What is the main objective of the study?
This observational, retrospective, new-user cohort study aims to 1. Estimate the incidence rate of acute pancreatitis in type 2 diabetes (T2D) patients newly exposed to canagliflozin and comparator antihyperglycemic agents (AHAs); and 2. Compare the hazard of acute pancreatitis in T2D patients newly exposed to canagliflozin vs. comparator AHAs, based on propensity-score matched cohorts.
Are there primary outcomes?Yes
Acute pancreatitis
Are there secondary outcomes?No
13. Study design
What is the design of the study?
Cohort study
14. Follow-up of patients
Will patients be followed up?Yes
Please describe duration of follow up
Two follow-up strategies will be implemented. In the intent-to-treat (ITT) approach, patients will be followed until the end of their observation time, regardless of any change in treatment. In the per protocol (PP, on-treatment) approach, patients will be followed while on the index treatment. Patients who switched from the index therapy to another medication will be censored.
15. Data analysis plan
Please provide a brief summary of the analysis method
Descriptive statistics of incidence rate will be presented. Comparative analysis will be conducted using both ITT and PP approaches for new users of canagliflozin vs. new users of alternative AHA therapy. Conditional Cox proportional hazards model based on time-to-first event approach, using propensity-score matched sets (with variable matching), will be used to estimate the comparative treatment effect size. The propensity score will be estimated through large-scale regularized regression, with demographics, all prior conditions/drugs/procedures, risk scores, utilization density as baseline covariates. Hochberg step-up procedure will be applied and adjusted p-values will be reported in addition to empirical p-values to control for multiple comparisons. A set of negative control outcomes will also be used to calibrate empirically observed p-values. Patients with a history of any form of pancreatitis will be evaluated and included in the study, if balance at baseline is achieved.
16. ENCePP seal
Are you requesting the ENCePP seal for this study?
No
17. Full protocol
Not submitted
18. Study Results
Please list the 5 most relevant publications using data from your study
ReferenceLink to web-publication
None
19. Other relevant documents
Conflict(s) of interest of
investigator(s)Not submitted
Composition of Steering Group and
ObserversNot submitted
Other documentsNot
submitted
Signed Code of
Conduct Checklist
Not submitted
Signed Code of Conduct Declaration
Not submitted
Signed Checklist for Study
Protocols
Not submitted
